Moreover, increased expression of SREBF1 and SREBF2 in MM cells correlated with significantly shorter progression-free survival (PFS) in both the CoMMpass (n = 747) and GSE9782 (n = 244) databases (Supplementary Fig. S1e). Here, SREBF1 is linked to Miyoshi myopathy.